57 related articles for article (PubMed ID: 12140761)
1. Human rgr: transforming activity and alteration in T-cell malignancies.
Leonardi P; Kassin E; Hernandez-Muñoz I; Diaz R; Inghirami G; Pellicer A
Oncogene; 2002 Aug; 21(33):5108-16. PubMed ID: 12140761
[TBL] [Abstract][Full Text] [Related]
2. The human Rgr oncogene is overexpressed in T-cell malignancies and induces transformation by acting as a GEF for Ras and Ral.
Osei-Sarfo K; Martello L; Ibrahim S; Pellicer A
Oncogene; 2011 Aug; 30(34):3661-71. PubMed ID: 21441953
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and biological analyses of Rgr RalGEF oncogene.
Martello LA; Pellicer A
Methods Enzymol; 2006; 407():115-28. PubMed ID: 16757319
[TBL] [Abstract][Full Text] [Related]
4. rgr oncogene: activation by elimination of translational controls and mislocalization.
Hernández-Muñoz I; Benet M; Calero M; Jiménez M; Díaz R; Pellicer A
Cancer Res; 2003 Jul; 63(14):4188-95. PubMed ID: 12874025
[TBL] [Abstract][Full Text] [Related]
5. The Rgr oncogene induces tumorigenesis in transgenic mice.
Jiménez M; Pérez de Castro I; Benet M; García JF; Inghirami G; Pellicer A
Cancer Res; 2004 Sep; 64(17):6041-9. PubMed ID: 15342385
[TBL] [Abstract][Full Text] [Related]
6. The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways.
Hernandez-Muñoz I; Malumbres M; Leonardi P; Pellicer A
Oncogene; 2000 May; 19(23):2745-57. PubMed ID: 10851075
[TBL] [Abstract][Full Text] [Related]
7. rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral.
D'Adamo DR; Novick S; Kahn JM; Leonardi P; Pellicer A
Oncogene; 1997 Mar; 14(11):1295-305. PubMed ID: 9178890
[TBL] [Abstract][Full Text] [Related]
8. The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress.
Velasco JA; Avila MA; Notario V
Oncogene; 1999 Jan; 18(3):689-701. PubMed ID: 9989819
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage.
Nandi S; Reinert LS; Hachem A; Mazan-Mamczarz K; Hagner P; He H; Gartenhaus RB
Oncogene; 2007 Apr; 26(16):2283-9. PubMed ID: 17016429
[TBL] [Abstract][Full Text] [Related]
10. Molecular cloning and characterization of human FGF8 alternative messenger RNA forms.
Ghosh AK; Shankar DB; Shackleford GM; Wu K; T'Ang A; Miller GJ; Zheng J; Roy-Burman P
Cell Growth Differ; 1996 Oct; 7(10):1425-34. PubMed ID: 8891346
[TBL] [Abstract][Full Text] [Related]
11. Distinct expression patterns and transforming properties of multiple isoforms of Ost, an exchange factor for RhoA and Cdc42.
Lorenzi MV; Castagnino P; Chen Q; Hori Y; Miki T
Oncogene; 1999 Aug; 18(33):4742-55. PubMed ID: 10467422
[TBL] [Abstract][Full Text] [Related]
12. Cloning and functional expression of the luteinizing hormone receptor complementary deoxyribonucleic acid from the marmoset monkey testis: absence of sequences encoding exon 10 in other species.
Zhang FP; Rannikko AS; Manna PR; Fraser HM; Huhtaniemi IT
Endocrinology; 1997 Jun; 138(6):2481-90. PubMed ID: 9165039
[TBL] [Abstract][Full Text] [Related]
13. A novel candidate oncogene, MCT-1, is involved in cell cycle progression.
Prosniak M; Dierov J; Okami K; Tilton B; Jameson B; Sawaya BE; Gartenhaus RB
Cancer Res; 1998 Oct; 58(19):4233-7. PubMed ID: 9766643
[TBL] [Abstract][Full Text] [Related]
14. Isolation of a novel oncogene, NET1, from neuroepithelioma cells by expression cDNA cloning.
Chan AM; Takai S; Yamada K; Miki T
Oncogene; 1996 Mar; 12(6):1259-66. PubMed ID: 8649828
[TBL] [Abstract][Full Text] [Related]
15. Human transcription factor Sp3: genomic structure, identification of a processed pseudogene, and transcript analysis.
Moran KM; Crusio RH; Chan CH; Grekova MC; Richert JR
Gene; 2004 Oct; 341():235-47. PubMed ID: 15474306
[TBL] [Abstract][Full Text] [Related]
16. Cloning and evaluation of RALGDS as a candidate for the tuberous sclerosis gene TSC1.
Humphrey D; Kwiatkowska J; Henske EP; Haines JL; Halley D; van Slegtenhorst M; Kwiatkowski DJ
Ann Hum Genet; 1997 Jul; 61(Pt 4):299-305. PubMed ID: 9365783
[TBL] [Abstract][Full Text] [Related]
17. Human and mouse DOCK10 splicing isoforms with alternative first coding exon usage are differentially expressed in T and B lymphocytes.
Alcaraz-García MJ; Ruiz-Lafuente N; Sebastián-Ruiz S; Majado MJ; González-García C; Bernardo MV; Alvarez-López MR; Parrado A
Hum Immunol; 2011 Jul; 72(7):531-7. PubMed ID: 21514340
[TBL] [Abstract][Full Text] [Related]
18. Tissue specific expression of alternative splice forms of human cyclic nucleotide gated channel subunit CNGA3.
Cassar SC; Chen J; Zhang D; Gopalakrishnan M
Mol Vis; 2004 Oct; 10():808-13. PubMed ID: 15534583
[TBL] [Abstract][Full Text] [Related]
19. Human interleukin-10 expression in T/natural killer-cell lymphomas: association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas.
Boulland ML; Meignin V; Leroy-Viard K; Copie-Bergman C; Brière J; Touitou R; Kanavaros P; Gaulard P
Am J Pathol; 1998 Oct; 153(4):1229-37. PubMed ID: 9777954
[TBL] [Abstract][Full Text] [Related]
20. Fli-1b is generated by usage of differential splicing and alternative promoter.
Dhulipala PD; Lee L; Rao VN; Reddy ES
Oncogene; 1998 Sep; 17(9):1149-57. PubMed ID: 9764825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
